Teleflex reported third quarter 2026 results that exceeded analyst expectations for both revenue and earnings. The company realized significant margin expansion and robust EPS growth, partially aided by one-time tariff refunds. Following the successful divestiture of its OEM business for $1.5 billion, Teleflex has transitioned its reporting structure into three global business units: Vascular, Interventional, and Surgical.
Key Highlights
- Completed the $1.5 billion OEM segment divestiture on August 3, 2026, resulting in after-tax proceeds of $1.25 billion used to pay down $700 million in debt.
- Aggressively returned capital to shareholders, repurchasing approximately $350 million of common stock through accelerated and open-market programs since July 1.
- Recognized a $25.3 million benefit from IEEPA tariff refunds, of which $16.5 million was included in the third quarter adjusted EPS calculation.
- Raised full year 2026 adjusted diluted EPS guidance to a range of $7.50 to $7.75, while maintaining pro forma constant currency revenue growth outlook at 3.5% to 4.5%.